Teva settles Sensipar patent dispute with Amgen
Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Teva’s product is a generic version of Amgen’s secondary hyperparathyroidism drug, Sensipar (cinacalcet HCl).
Cinacalcet is a calcium-sensing receptor used to treat adult patients with chronic kidney disease on dialysis. It can also be used for the treatment of hypercalcemia.
Sensipar lost patent exclusivity in March last year. Teva said that prior to the settlement, it recently received approval for the drug and launched it in the US.
Under the terms of the agreement, Teva has agreed to stop selling the generic drug until its licence date in 2021, or earlier under certain circumstances.
In its announcement, published on Wednesday, January 2, Israel-based Teva said it will pay Amgen an undisclosed amount as part of a settlement, which will end patent infringement litigation between the two companies.
The terms of the settlement remain confidential.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
